Travere Therapeutics, Inc. (TVTX)

NASDAQ: TVTX · USD

$50.8

-0.05 (-0.1%)· Recorded snapshot

Market cap	4.8B
Revenue (ttm)	591.3M
Net income (ttm)	-43.5M
EPS (ttm)	-$0.48
Shares out	94.3M
P/E (forward)	13.5x
Volume	1,166,279
Beta	1.14

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 591.3M
Net income (ttm): -43.5M
EPS (ttm): -$0.48
P/E (forward): 13.5x
Market cap: 4.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E13.5

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-236.4

P25 n/aP50 n/aP75 n/a

ROIC-25.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TVTX indicators

Market & fundamental data

Available fields

224

Groups with data

Currency

USD

Showing 224 of 224 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001438533
Company name	Travere Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	89422G107
Earnings date	2026-11-02
Earnings time	amc
Employees	497
Employees change	112
Employees growth	29.09%
Enterprise value	$4.9B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US89422G1076
Last 10-K release date	2026-02-19
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$4.8B
Market cap category	Mid-Cap
Next earnings date	2026-11-02
Options	Yes
Price	$50.83
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	TVTX
U.S. state	California
Website	https://www.travere.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	55.86x
Earnings yield	-0.94%
EV/EBITDA	212.01x
EV/FCF	52.4x
EV/Sales	8.21x
FCF / EV yield	1.91%
FCF yield	1.96%
Forward EV/Sales	5.1x
Forward P/E	13.53x
Forward P/S	4.96x
P/(FCF - SBC) ratio	147.63x
P/(OCF - SBC) ratio	147.63x
P/B ratio	195.4x
P/FCF ratio	51.03x
P/OCF ratio	51.03x
P/S ratio	8x
Price/EBITDA ratio	206.43x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-6.84%
EBITDA margin	3.87%
FCF margin	15.68%
Gross margin	59.21%
Operating margin	-6.84%
Pretax margin	-11.34%
Profit margin	-7.35%
Profit per employee	$-87,453
Revenue per employee	$1.2M
ROA	-3.73%
ROA (5Y)	-21.5%
ROCE	-6.25%
ROE	-236.35%
ROE (5Y)	-178.06%
ROIC	-25.77%
SBC / revenue	10.26%
Tax / revenue	0.1%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
FCF growth (Q)	1,065.38%
Gross profit growth	300.46%
Gross profit growth (Q)	100.41%
Net income growth years	1
OCF growth (Q)	1,065.38%
Revenue growth	77.12%
Revenue growth (Q)	48.17%
Revenue growth (QoQ)	33.32%
Revenue growth 10Y	17.22%
Revenue growth 3Y	69.94%
Revenue growth 5Y	23.7%
Revenue growth quarters	12
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$63.4M
EBIT	$-40.5M
EBITDA	$22.9M
EPS	$-0.48
FCF per share	$0.98
Financing cash flow	$153.1M
Free cash flow	$92.7M
Free cash flow minus SBC	$32M
Gross profit	$350.1M
Income taxes	$605,000
Investing cash flow	$-203M
Net borrowing	$105.2M
Net cash flow	$42.6M
Net income	$-43.5M
Operating cash flow minus SBC	$32M
Operating income	$-40.5M
Revenue	$591.3M
Stock-based compensation	$60.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.76
Book value per share	$0.26
Debt / EBITDA	22.59
Debt / equity	25.16
Debt / FCF	6.65
Goodwill	$753,000
Interest coverage	-4.27
Long-term assets	$184.2M
Long-term liabilities	$622.8M
Net cash (debt)	$-127.7M
Net cash / market cap	-2.7%
Net debt / EBITDA	5.57
Net debt / equity	5.21
Net debt / FCF	1.38
Piotroski F-Score	5
Property, plant and equipment	$12M
Shareholders' equity	$24.5M
Tangible book value	$-107M
Tangible book value per share	$-1.14
Total assets	$799.4M
Total cash	$489.2M
Total debt	$616.9M
Total liabilities	$774.8M
WACC	9.46%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.87
Current assets	$615.1M
Current liabilities	$152M
Current ratio	4.05
Inventory turnover	40.46
Net working capital	$-19.9M
Quick ratio	3.76
Working capital	$463.1M
Working capital turnover	1.81

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-7.89%
Dividend yield	0%
Shareholder yield	-7.89%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	166.96%
10Y return CAGR	10.32%
10Y total return	166.96%
150-day SMA	$52.16
1D price change	-0.1%
1M price change	-14.49%
1M total return	-14.49%
1W price change	-3.33%
1W total return	-3.33%
1Y price change	70.74%
1Y return CAGR	70.81%
1Y total return	70.74%
20-day SMA	$52.70
200-day SMA	$46.40
3M price change	-10.32%
3M total return	-10.32%
3Y price change	647.5%
3Y return CAGR	95.5%
3Y total return	647.5%
50-day SMA	$59.65
50-day SMA vs 200-day SMA	50over200
52-week high	$68.73
52-week high date	2026-09-11
52-week low	$22.59
52-week low date	2026-01-13
5Y price change	94.01%
5Y return CAGR	14.18%
5Y total return	94.01%
6M price change	24.55%
6M total return	24.55%
All-time high	$68.73
All-time high date	2026-09-11
All-time low	$2.55
All-time low date	2012-12-27
Average true range (ATR)	$2.21
Average volume	2.1M
Beta (1Y)	2.16
Beta (2Y)	1.79
Beta (5Y)	1.14
Change from 52-week high	-26.04%
Change from 52-week low	125.01%
Change from all-time high	-26.04%
Change from all-time low	1,893.33%
Change from open	1.07%
Day's gap	-1.16%
Dollar volume	$59.3M
High price	$50.83
Low price	$49.76
Monthly RSI	62.54
Open price	$50.29
Position in 52-week range	100%
Premarket change	0%
Premarket close	$50.88
Premarket price	$50.88
Premarket volume	6.7K
Previous close	$50.88
Price vs 150-day SMA	-2.54%
Price vs 20-day SMA	-3.56%
Price vs 200-day SMA	9.54%
Price vs 50-day SMA	-14.79%
Relative volume	0.55
RSI	36.66
Sharpe ratio	1.07
Sharpe ratio (3Y)	1.25
Sharpe ratio (5Y)	0.49
Sortino ratio	2.15
Sortino ratio (3Y)	2.22
Sortino ratio (5Y)	0.82
Volume	1.2M
Weekly RSI	47.94
YTD price change	33.03%
YTD total return	33.03%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	93.2M
Float percentage	98.9%
Shares change (QoQ)	1.75%
Shares change (YoY)	7.89%
Shares held by insiders	1.1%
Shares held by institutions	116.56%
Shares outstanding	94.3M
Short % of float	13.58%
Short % of shares	13.43%
Short ratio	8.2 days

Deeper analysis on TVTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TVTX report

Is a complete TVTX research report available?

No complete published report is available for Travere Therapeutics, Inc. (TVTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Travere Therapeutics, Inc. (TVTX)

Price

Financial snapshot

Fair-value bridge

Latest news · TVTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TVTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TVTX

Frequently asked questions